9 completed, 1 terminated. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
Follow BI 2536: new trials by email Literature Review of BI 2536 trials Research Report on BI 2536
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors BI 2536, high performance liquid chromatography, mass spectrometry - Breast Cancer, Endometrial Cancer | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 76 | 2007-07-01 | 2013-10-07 |
| Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer BI 2536, intravenous, Gemcitabine, intravenous - Pancreatic Neoplasms | Phase 1 | Terminated | Boehringer Ingelheim | 12 | 2007-06-01 | 2014-08-13 |
| BI 2536 Second Line Monotherapy in SCLC BI 2536 - Carcinoma, Small Cell | Phase 2 | Completed | Boehringer Ingelheim | 23 | 2007-02-14 | 2022-06-22 |
| Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer BI 2536, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Boehringer Ingelheim | 41 | 2006-10-01 | 2014-08-08 |
| BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia BI 2536 - Leukemia, Myeloid, Acute | Phase 2 | Completed | Boehringer Ingelheim | 71 | 2006-10-01 | 2014-05-16 |
| Phase II Study of BI 2536 in Prostate Cancer BI 2536 - Prostatic Neoplasms | Phase 2 | Completed | Boehringer Ingelheim | 20 | 2006-09-01 | 2014-05-16 |
| Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer BI 2536 - Pancreatic Neoplasms | Phase 2 | Completed | Boehringer Ingelheim | 89 | 2006-08-01 | 2022-05-04 |
| Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer BI 2536 - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Boehringer Ingelheim | 96 | 2006-07-25 | 2022-06-21 |
| Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) BI 2536 - Lymphoma | Phase 1 | Completed | Boehringer Ingelheim | 41 | 2005-07-01 | 2024-12-20 |
| Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit BI 2536 - Neoplasms | Phase 1 | Completed | Boehringer Ingelheim | 70 | 2004-08-01 | 2024-12-20 |
Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Small Cell (1) · Desmoplastic Small Round Cell Tumor (1) · Endometrial Neoplasms (1) · Fibrosarcoma (1) · Head and Neck Neoplasms (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Leukemia, Myeloid, Acute (1) · Liposarcoma (1)
Boehringer Ingelheim (9) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Germany (3) · Austria (2) · United States (2) · Belgium (1) · Canada (1) · United Kingdom (1)
Julie M. Vose, MD (1) · Patrick Schoffski, MD, MPH (1)